J4 ›› 2012, Vol. 38 ›› Issue (6): 1073-1076.

Previous Articles     Next Articles

Treatment effect of salidroside combined with bone marrow mesenchymal stem cells on rats with Parkinson’s disease

FAN Dong-yan1,WANG Ping2,CHEN Yu-bing3   

  1. (1.Department of Preventive Medicine,Medical School,Tibet University,Lhasa 850000,China|2.Department |of Otorhinolaryngology and Head-Neck Surgery,First Hospital,Jilin University,Chan
    gchun 130021,China|3. Depatment of Nuclear Medicine,Second Hospital,J ilin University,Changchun 130041,China)
  • Received:2012-05-23 Online:2012-11-28 Published:2012-11-28

Abstract:

 To study the treatment effect of salidroside combined with bone marrow mesenchymal stem cells (BMSCs) on rats with Parkinson’s disease(PD),and to provide experiment basis for curring Parkinson’s disease.Methods The BMSCs were cultured adherently,the cell surface molecules were detected by immunofluorescence.The effect of 10 mg·L-1 salidroside on the proliferation and differentiation of BMSCs was detected by MTT.60  Wistar rats were randomly divided into sham group,model group,salidroside treatment group,BMSCs treatment group,and  salidroside and BMSCs combination therapy group.The behavior changes were detected at a specific time  and  the levels of tyrosin hydroxylase(TH) mRNA in brain tissue were detected.Results The setm cell markers CD29 and CD44 were expressed  successfully.Compared with control group,the proliferation of BMSCs got bigger and the plateau got longer after treated with salidroside.The rotation number of PD model rats was the least compared with the other groups(P<0.05).The expression level of TH mRNA wasdecreased.The behavior abnormalities of PD model rats were improved and the level of TH mRNA was increased  after treated with salidroside and  BMSCs compared with the other groups(P<0.05).Conclusion The treatment efficacy of salidroside combined with BMSCs on PD rats is better than salidroside or BMSCs alone.

Key words: salidroside, bone mesenchymal stem cells, Parkinson’s disease

CLC Number: 

  • R745